OP0288 MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY
Izadi Z, Gianfrancesco M, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Lawson-Tovey S, Trupin L, Rush S, Schmajuk G, Jacobsohn L, Katz P, Al Emadi S, Wise L, Gilbert E, Valenzuela-Almada M, Duarte-Garcia A, Sparks J, Hsu T, D’silva K, Serling-Boyd N, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J. OP0288 MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY. Annals Of The Rheumatic Diseases 2021, 80: 175.2-176. DOI: 10.1136/annrheumdis-2021-eular.446.Peer-Reviewed Original ResearchAcute respiratory distress syndromeDevelopment of acute respiratory distress syndromeTime of COVID-19 diagnosisNegative predictive valuePositive predictive valueGlobal Rheumatology AllianceRheumatic diseasesBristol-Myers SquibbGrant/research supportPredictive valueArea under curveCOVID-19 Global Rheumatology AllianceRisk factors associated with acute respiratory distress syndromeGlobal cohort of patientsPre-existing rheumatic diseaseRisk of acute respiratory distress syndromeAnti-CD20 monoclonal antibodyAcute respiratory distress syndrome diagnosisTumor necrosis factor inhibitorsBristol-MyersCOVID-19 diagnosisRespiratory distress syndromeCohort of patientsInterstitial lung diseaseLife-threatening complicationsOP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA)
Ugarte-Gil M, Alarcon G, Seet A, Izadi Z, Reategui Sokolova C, Clarke A, Wise L, Pons-Estel G, Santos M, Bernatsky S, Mathias L, Lim N, Sparks J, Wallace Z, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Lawson-Tovey S, Trupin L, Rush S, Schmajuk G, Katz P, Jacobsohn L, Al Emadi S, Gilbert E, Duarte-Garcia A, Valenzuela-Almada M, Hsu T, D’silva K, Serling-Boyd N, Dieudé P, Nikiphorou E, Kronzer V, Singh N, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Gianfrancesco M, Yazdany J. OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA). Annals Of The Rheumatic Diseases 2021, 80: 173.2-175. DOI: 10.1136/annrheumdis-2021-eular.2984.Peer-Reviewed Original ResearchSystemic lupus erythematosusChronic renal diseaseModerate/high disease activityNon-invasive ventilationSevere COVID-19 outcomesBristol-Myers SquibbDisease activityGrant/research supportRenal diseaseCOVID-19 outcomesCOVID-19 diagnosisDrug monotherapyImmunomodulatory therapyGlobal Rheumatology AllianceMembrane oxygenationCOVID-19 Global Rheumatology AllianceNational Institute for Health ResearchMale sexModerate to high daily dosesSLE adult patientsBristol-MyersSystemic lupus erythematosus patientsSystemic lupus erythematosus therapyCardiovascular diseaseOdds of poor outcomeOP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE
Sparks J, Wallace Z, Seet A, Gianfrancesco M, Izadi Z, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Lawson-Tovey S, Trupin L, Rush S, Schmajuk G, Katz P, Jacobsohn L, Al Emadi S, Wise L, Gilbert E, Duarte-Garcia A, Valenzuela-Almada M, Hsu T, D’silva K, Serling-Boyd N, Dieudé P, Nikiphorou E, Kronzer V, Singh N, Ugarte-Gil M, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Yazdany J. OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE. Annals Of The Rheumatic Diseases 2021, 80: 2.1-4. DOI: 10.1136/annrheumdis-2021-eular.1632.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsTNFi usersInterleukin-6 inhibitorsJanus kinase inhibitorsRituximab usersCOVID-19 severityBristol-Myers SquibbRA disease activityGrant/research supportAssociated with greater oddsRheumatoid arthritisCOVID-19 outcomesPoor COVID-19 outcomesGlobal Rheumatology AllianceSynthetic DMARDsCOVID-19 Global Rheumatology AllianceDMARD useDisease activityBristol-MyersJanus kinase inhibitor usePropensity scoreTumor necrosis factor inhibitor useRheumatic diseasesBaseline useOptimal timing of vaccination